Rotigotine Objectively Improves Sleep in Parkinson’s Disease: An Open-Label Pilot Study with Actigraphic Recording

Table 3

Nocturnal actigraphic results before (T0) and during (T1) rotigotine treatment in 10 patients with sleep efficiency 85% at T0.

Scale	T0	T1
SL (min)	47 (23–66)	24 (7–40)	0.241
TST (min)	343 (289–373)	330 (286–397)	0.508
SE (%)	68 (51–82)	73 (69–83)	0.017
WASO (min)	147 (114–215)	109 (81–152)	0.013
Number of wake episodes	20 (19–22)	21 (16–28)	0.646
Mean duration of wake episodes (min)	11 (8–14)	7 (5–9)	0.005
ACmean	47 (36–69)	35 (28–44)	0.005
ACmedian	11 (5–30)	8 (0–17)	0.028
ACindex	64 (50–79)	65 (43–73)	0.114

SL = sleep latency; min = minutes; TST = total sleep time; SE = sleep efficiency; WASO = wake after sleep onset; ACmean = activity mean score; ACmedian = activity median score; ACindex = activity index. Data are expressed as median (25th–75th percentiles). = .